OBJECTIVE: To evaluate the performance parameters of FDG PET/CT in patients with Takayasu arteritis at diagnosis and during immunosuppression. METHODS: Retrospective analysis of 60 FDG PET/CT studies in 51 patients was performed (17 scans at diagnosis out of which 4 had follow-up scans also and 43 scans on immunosuppression). The degree of FDG uptake in the vessels was assessed visually using a 4-point scale and maximum standardized uptake value (SUVmax), SUVratio, extent of vasculitis and association with ESR were calculated. RESULTS: PET/CT was positive for active vasculitis in all 17 patients at diagnosis. The mean SUVmax and mean SUV ratio of the active areas were 5.1 ± 3.0 and 3.2 ± 1.9, respectively. On immunosuppression, PET scan was positive for active vasculitis in 14/43 (32.5%) scans. The mean SUVmax and mean SUVratio of the active areas were 1.7 ± 2.1 and 0.95 ± 1.2, respectively. There was significant difference between the mean SUVmax and mean SUVratio at diagnosis and on immunosuppression, respectively (P < .01). The median number of vascular segments in each uptake grade group was also statistically different (P < .01) between scans at diagnosis and on immunosuppression. The median ESR level in PET positive scans was 29 mm/hour (2-53), whereas in PET negative scans was 35.5 mm/hour (6-50) and the difference was not statistically significant. CONCLUSION: FDG PET/CT showed good sensitivity to detect active vasculitis at diagnosis and during immunosuppression. The change in SUVmax between the successive FDG PET/CT scans may give an objective assessment of response to immunosuppression.
OBJECTIVE: To evaluate the performance parameters of FDG PET/CT in patients with Takayasu arteritis at diagnosis and during immunosuppression. METHODS: Retrospective analysis of 60 FDG PET/CT studies in 51 patients was performed (17 scans at diagnosis out of which 4 had follow-up scans also and 43 scans on immunosuppression). The degree of FDG uptake in the vessels was assessed visually using a 4-point scale and maximum standardized uptake value (SUVmax), SUVratio, extent of vasculitis and association with ESR were calculated. RESULTS: PET/CT was positive for active vasculitis in all 17 patients at diagnosis. The mean SUVmax and mean SUV ratio of the active areas were 5.1 ± 3.0 and 3.2 ± 1.9, respectively. On immunosuppression, PET scan was positive for active vasculitis in 14/43 (32.5%) scans. The mean SUVmax and mean SUVratio of the active areas were 1.7 ± 2.1 and 0.95 ± 1.2, respectively. There was significant difference between the mean SUVmax and mean SUVratio at diagnosis and on immunosuppression, respectively (P < .01). The median number of vascular segments in each uptake grade group was also statistically different (P < .01) between scans at diagnosis and on immunosuppression. The median ESR level in PET positive scans was 29 mm/hour (2-53), whereas in PET negative scans was 35.5 mm/hour (6-50) and the difference was not statistically significant. CONCLUSION:FDG PET/CT showed good sensitivity to detect active vasculitis at diagnosis and during immunosuppression. The change in SUVmax between the successive FDG PET/CT scans may give an objective assessment of response to immunosuppression.
Authors: J Meller; F Strutz; U Siefker; A Scheel; C O Sahlmann; K Lehmann; M Conrad; R Vosshenrich Journal: Eur J Nucl Med Mol Imaging Date: 2003-04-04 Impact factor: 9.236
Authors: Martin Fuchs; Matthias Briel; Thomas Daikeler; Ulrich A Walker; Helmut Rasch; Scott Berg; Quinn K T Ng; Heike Raatz; David Jayne; Ina Kötter; Daniel Blockmans; Maria C Cid; Sergio Prieto-González; Peter Lamprecht; Carlo Salvarani; Zaharenia Karageorgaki; Richard Watts; Raashid Luqmani; Jan Müller-Brand; Alan Tyndall; Martin A Walter Journal: Eur J Nucl Med Mol Imaging Date: 2011-11-10 Impact factor: 9.236
Authors: W P Arend; B A Michel; D A Bloch; G G Hunder; L H Calabrese; S M Edworthy; A S Fauci; R Y Leavitt; J T Lie; R W Lightfoot Journal: Arthritis Rheum Date: 1990-08
Authors: Martin A Walter; Ralph A Melzer; Christian Schindler; Jan Müller-Brand; Alan Tyndall; Egbert U Nitzsche Journal: Eur J Nucl Med Mol Imaging Date: 2005-03-04 Impact factor: 9.236
Authors: G S Kerr; C W Hallahan; J Giordano; R Y Leavitt; A S Fauci; M Rottem; G S Hoffman Journal: Ann Intern Med Date: 1994-06-01 Impact factor: 25.391
Authors: Elena Incerti; Enrico Tombetti; Federico Fallanca; Elena M Baldissera; Pierpaolo Alongi; Elisabetta Tombolini; Silvia Sartorelli; Maria Grazia Sabbadini; Maurizio Papa; Francesco De Cobelli; Justin C Mason; Luigi Gianolli; Angelo A Manfredi; Maria Picchio Journal: Eur J Nucl Med Mol Imaging Date: 2017-02-08 Impact factor: 9.236
Authors: L Dellavedova; M Carletto; P Faggioli; A Sciascera; A Del Sole; A Mazzone; L S Maffioli Journal: Eur J Nucl Med Mol Imaging Date: 2015-08-08 Impact factor: 9.236